Last reviewed · How we verify
TGRX-678
TGRX-678 is a small molecule that targets the SGLT2 receptor.
TGRX-678 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | TGRX-678 |
|---|---|
| Sponsor | Shenzhen TargetRx Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, TGRX-678 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful for the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients (PHASE3)
- TGRX-678 Pharmacokinetic Mass Balance (PHASE1)
- TGRX-678 Phase I Oral Pharmacokinetic Study (PHASE1)
- TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients (PHASE1)
- TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia (PHASE1)
- TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TGRX-678 CI brief — competitive landscape report
- TGRX-678 updates RSS · CI watch RSS
- Shenzhen TargetRx Co., Ltd. portfolio CI